State Street
JUNO

State Street’s Juno Therapeutics, Inc. JUNO Stock Holding History

State Street’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,969,053
Closed -$90M – 3818
2017
Q4 		$90M Sell
1,969,053
-702,070
-26% -$35M 0.01% 1088
2017
Q3 		$120M Sell
2,671,123
-565,261
-17% -$19.3M 0.01% 891
2017
Q2 		$96.7M Buy
3,236,384
+222,754
+7% +$5.5M 0.01% 976
2017
Q1 		$66.9M Sell
3,013,630
-402,114
-12% -$8.62M 0.01% 1152
2016
Q4 		$64.4M Buy
3,415,744
+478,044
+16% +$11.7M 0.01% 1134
2016
Q3 		$88.2M Buy
2,937,700
+1,278,908
+77% +$39.8M 0.01% 945
2016
Q2 		$63.8M Buy
1,658,792
+440,324
+36% +$18.3M 0.01% 1062
2016
Q1 		$46.4M Buy
1,218,468
+210,019
+21% +$7.32M 0.01% 1204
2015
Q4 		$44.3M Buy
1,008,449
+149,937
+17% +$7.44M ﹤0.01% 1233
2015
Q3 		$34.9M Buy
858,512
+326,140
+61% +$14.3M ﹤0.01% 1371
2015
Q2 		$28.4M Buy
532,372
+460,441
+640% +$24.4M ﹤0.01% 1629
2015
Q1 		$4.36M Buy
+71,931
New +$3.49M ﹤0.01% 2637

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

State Street's JUNO Position: Q1 2018 in Review

State Street sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,969,053 shares — an estimated $90M sold.

State Street first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $120M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • State Street reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • State Street sold 1,969,053 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $90M.
  • State Street first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • State Street's Juno Therapeutics, Inc. position peaked at $120M in Q3 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on State Street's 13F filing for Q1 2018, filed 15 May 2018.